SOMATONORM 4 IU ▼

PRESCRIBING INFORMATION

PRESENTATION
A vial of sterile lyophilised powder of somatrem corresponding to 4 IU of human somatotropin (also containing aminoacetic acid and sodium phosphate as stabilisers) and supplied with a 2 ml ampoule of water for injections for use in the reconstitution of the injection.

USES
The treatment of short stature caused by decreased or absent secretion of pituitary growth hormone. The diagnosis should be verified by appropriate investigations of pituitary function by a specialist medical practitioner.

DOSAGE AND ADMINISTRATION
Route of administration:
By intramuscular injection.

Recommended dosage:
The dosage should be calculated according to the patient's body weight. Generally a dose of 0.5 IU/kg body weight per week is recommended. This weekly dose should be divided into 2 or 3 intramuscular injections.

PREPARATION OF SOLUTION
The solution is prepared by adding 2 ml of water for injections to the lyophilised substance in the vial. Gently dissolve the drug with a slow swirling motion. Do not shake vigorously as this may cause denaturation of the active ingredient.

CONTRA-INDICATIONS, WARNINGS, ETC.
Only patients with unfused epiphyses should be treated. Diabetes mellitus.

Precautions:
Patients treated with Somatonorm should be regularly assessed by a specialist in child growth. This assessment should include determination of growth response and endocrinological status, as relative deficiencies of other pituitary hormones may be exposed or exacerbated by an adequate growth response.

Overdosage:
Acute overdosage is unlikely and does not represent a hazard to the patient. The consequences of long term administration of doses above the normal therapeutic range are unknown.

Side-effects:
Clinical experience with Somatonorm is limited and recipients may develop antibody to growth hormone and E. coli protein. However, as with pituitary derived hormone, only in very rare instances has growth retardation occurred. No other adverse reactions have been noted.

PHARMACEUTICAL PRECAUTIONS
Store at 2–8°C. Reconstituted Somatonorm may be stored in the refrigerator for 24 hours before use.

LEGAL CATEGORY
POM.

PACKAGE QUANTITIES
Combined package containing one vial of somatrem 4 IU and one ampoule of 2 ml water for injections.

FURTHER INFORMATION
Somatonorm is produced using recombinant DNA technology. Somatrem is the British Approved Name for methionyl human somatotropin.

PRODUCT LICENCE NUMBER
0022/0060 P.A. 187/28/1

N.H.S. Price £ 28



Eliminates the risk of transmissible diseases through recombinant DNA technology.

Extremely low levels of ECP achieved by leading purification technology.

For the past [illegible] KabiVitrum has been in the forefront of hGH research. The introduction of Somatonorm® reflects KabiVitrum's continuing commitment in the field of growth and growth factors.

GROWTH SERVICE KABIVITRUM

KabiVitrum Ltd • KabiVitrum House • Riverside Way • Uxbridge • Middlesex UB8 2YF • Tel: (0895) 51144

KabiVitrum (Eire) • Cahill May Roberts Ltd • PO Box 1090 • Chapelizod • Dublin 20 • Tel: Dublin 267111

Taurine– the next step forward in infant nutrition.



For over 60 years, Wyeth has built a reputation for developing infant formulae that represent the very best that knowledge and technology will allow.

Nevertheless, work has continued towards both a fuller understanding of the differences between infant formulae and breast milk, and clarification of the possible metabolic significance these differences may have in the newborn.

Research pioneered by Wyeth shows that the sulphonic amino acid, taurine, is abundant in breast milk[1] and may have a role in bile functions[2] and the developing central nervous system,[3] retina,[4] and myocardium.[5]

Breast milk should be the natural standard for all infant formulae. For this reason, taurine is now included in all Wyeth ready-to-feed and powder formulae to ensure continuity of good nutrition for bottle-fed babies throughout infancy.

Wyeth infant formulae with taurine – now eve



Breast milk is best for babies. Infant formula is intended to replace or supplement breast milk when breast feeding is not possible or is insufficient, or when mothers elect not to breast feed. Good maternal nutrition is important for the preparation and maintenance of breast feeding. Extensive or prolonged use of partial bottle feeding, before breast feeding has been well established, could make breast feeding difficult to maintain. A decision not to breast feed could be difficult to reverse. Professional advice should be followed on all matters of infant feeding. Infant formula should always be prepared and used as directed. Unnecessary or improper use of infant formula could present a health hazard. Social and financial implications should be considered when selecting the method of infant feeding.

References: 1. Rassin D.K., Sturman J.A., Gaull G.E. (1978). Taurine and other free amino acids in milk of man and other mammals. Early Human Development 2/1, 1. **2.** Jäavenpää A.L., Rasin D.K., Kuitunen P., Gauli G.E., Räihä N.C.R. (1983). Feeding the low birthweight infant: Ill Diet influences bile metabolism. Paediatrics 72, 677. **3.** Sturman J.A., Gaull G.E. (1976). Taurine in the brain and liver of the developing human and rhesus monkey. In: Huxtable R., Barbeau A. (eds). Taurine. Raven Press, New York, pp 73-84. **4.** Sturman J.A., Wen G.Y., Wisniewski H.M., Neuringer M.D. (1984). Retinal degeneration in primates raised on synthetic infant formula. Int. J. Dev. Neurosci. 2, 121. **5.** Huxtable R.J., Sebring L.A. (1983). Cardiovascular actions of taurine. In: Kuriyama K., Huxtable R.J., Iwata H. (eds). Sulfur Amino Acids: Biochemical and Clinical Aspects, Alan R. Liss, New York, pp 5-37.

ı closer to breast milk.

Wyeth Nutrition
Leading the way

*Trade mark.

Wyeth Nutrition, Huntercombe Lane South, Taplow, Maidenhead, Berks. SL6 0PH.

Further information, including a review of the role of taurine is contained in a booklet "Taurine in Infant Nutrition" available on request from Wyeth Nutrition.

THE HEINZ FELLOWSHIPS OF THE BRITISH PAEDIATRIC ASSOCIATION

H. J. Heinz Company Limited generously endows Fellowships in Paediatrics which are administered by the British Paediatric Association.

Two or three Fellowships will be offered each year, the number and type awarded in any one year depending on circumstances and the calibre of applicants available.

The types of Fellowship, which are open to men or women are:

A To enable paediatricans from any part of the Commonwealth overseas to spend up to twelve weeks in the United Kingdom, meeting British Paediatricians and seeing something of their work. Preference will be given to those recently established in an academic career who can arrange their visit to allow attendance at the Annual Meeting of the British Paediatric Association in April 1988

C To enable paediatricians from the United Kingdom of Registrar, Senior Registrar or Consultant status, but in the early years of professional life, to make a short working visit (up to three months) to a centre in a developing country, teaching or conducting research so as to benefit both fellow and hosts.

Applications for A Fellowships must be received by the British Paediatric Association not later than 31st December 1986

Applications for C Fellowships can be accepted by 31st January 1987 or 31st July 1987

The conditions for the Fellowships and applications forms may be obtained from the British Paediatric Association, 5 St Andrew's Place, Regent's Park, London NW1 4LB

He's running on the new M2.

He has found that a B.D. dose of the new Humulin M2 closely matches his daily insulin requirements.

The 20/80 mixture of Humulin S (soluble) and Humulin I (isophane) provides both a rapid action and prolonged effect that fit his needs.

In another patient with a lower soluble insulin requirement, Humulin M1, containing 10% soluble and 90% isophane, might be more suitable.

All this with a consistency and convenience that cannot usually be achieved with free mixing.[1]

Like all Humulin products, M1 and M2 share the unique benefits of human insulin produced by genetic engineering; low immunogenicity,[2] unlimited future supply and at a cost comparable with pork or enzymatically modified insulins.



Humulin
Human insulin (crb)
MIXTURES

Consistency and convenience with low immunogenicity

Epilim®
sodium valproate

In a wide range of epilepsies

Presentation 1. Epilim 200 Enteric Coated. A lilac-coloured enteric coated tablet containing 200mg sodium valproate. 2. Epilim 500 Enteric Coated. A lilac-coloured enteric coated tablet containing 500mg sodium valproate. 3. Epilim 100mg crushable tablets. A white scored tablet containing 100mg sodium valproate. 4. Epilim Syrup. A red, cherry-flavoured syrup containing 200mg sodium valproate per 5ml. 5. Epilim Liquid. A red, cherry-flavoured, sugar-free liquid containing 200mg sodium valproate per 5ml. **Indications** In the treatment of generalised, partial or other epilepsies. In women of child-bearing age Epilim should be used only in severe cases or in those resistant to other treatment. **Dosage and Administration** To be taken with or after food. Epilim may be given twice daily. Enteric coated tablets should be swallowed whole. **Monotherapy** *Adults:* Start at 600mg/daily increasing by 200mg at 3 day intervals until control is achieved. (Maximum dose 2,500mg per day). *Children over 20kg:* Initially 400mg/day with spaced increases until control is achieved. (Usually within the range 20-30mg/kg body weight per day). *Children under 20kg:* 20mg/kg of body weight per day: in severe cases may be increased up to 40mg/kg day. Increases above this only if plasma valproic acid levels, clinical chemistry and haematological parameters can be monitored. **Combined Therapy** It may be necessary to raise the dose when used with anticonvulsants which induce liver enzyme activity. Dosage of barbiturates should be reduced if sedation is observed. Optimum dosage is mainly determined by seizure control and routine measurement of plasma levels is unnecessary. **Contra-indications, Warnings; Contra-indication:** Active liver disease. **Side effects:** Liver dysfunction including hepatic failure resulting in fatalities has occurred in patients whose treatment included valproic acid or sodium valproate. The incidents mainly occurred during the first 6 months of therapy. Clinical symptoms are more helpful than laboratory investigations in the early stages of hepatic failure. The onset of an acute illness, especially within the first 6 months, which may include symptoms of vomiting, lethargy or weakness, drowsiness, anorexia, jaundice or loss of seizure control is an indication for immediate withdrawal of the drug. Evidence to date does not establish which investigation could predict this possible adverse effect: measurement of liver function should be performed in the first 6 months of therapy in those who seem most at risk. Hyperammonaemia without hepatic damage can occur, it is usually transient, but may occasionally present clinically. If so Epilim should be discontinued. Valproic acid inhibits platelet aggregation. Thrombocytopenia has been reported. Spontaneous bruising or bleeding is an indication for withdrawal of medication. Pancreatitis, tremor, weight gain, transient hair loss, increased alertness, aggressiveness, hyperactivity, amenorrhoea, stupor and oedema have been reported. **Drug Interactions** Epilim may potentiate monoamine oxidase inhibitors and other anti-depressants. Loss of efficacy of oral contraceptive agents does not appear to be a problem. **Women of Childbearing Age** Valproic acid and sodium valproate, like certain other anti-convulsants, have been shown to be teratogenic in animals. In women of childbearing age the benefits of these compounds should be weighed against the possible hazard suggested by these findings and their pregnancies should be carefully monitored. **Product Licence Numbers** Epilim 200 Enteric Coated 0623/0006. Epilim 500 Enteric Coated 0623/0005. Epilim 100mg crushable tablets 0623/0015. Epilim Syrup 0623/0004. Epilim Liquid 0623/0016. **NHS Cost** Epilim 200 Enteric Coated 100 tablets, £6.59. Epilim 500 Enteric Coated 100 tablets, £16.45. Epilim 100mg crushable tablets 100 tablets, £3.99. Epilim Syrup 200ml, £4.03. Epilim Liquid 200ml, £4.03. Further information is available from: Labaz: Sanofi UK Ltd., Floats Rd., Wythenshawe, Manchester M23 9NF. Tel: 061-945 4161.

Epilim®
sodium valproate

helps to maintain the normality of life

Monatsschrift Kinderheilkunde

Organ der Deutschen Gesellschaft für Kinderheilkunde

134. Band
Heft 6
Juni 1986

Springer-Verlag
Berlin Heidelberg New York Tokyo

Vorträge der 81. Tagung der Deutschen Gesellschaft für Kinderheilkunde vom 1. bis 4. September 1985 in Frankfurt/Main

Indexed in Current Contents

Monatsschr Kinderheilkd (1986) 134, 6

Annual subscription: DM 278,— plus postage



Pure innovation revealed

The range of human insulins from Nordisk and Wellcome

Full prescribing information available on request from either:-

Nordisk-UK
Highview House
Tattenham Crescent
Epsom KT18 5QJ
Tel. No: Burgh Heath (07373) 60621

The Wellcome Foundation Ltd.
Crewe Hall
Crewe
Cheshire CW1 1UB
Tel. No: Crewe (0270) 583151

Human
● INSULATARD
(Isophane Insulin Injection [NPH], highly purified human insulin [emp])

Human
● VELOSULIN
(Neutral Insulin Injection, highly purified human insulin [emp])

Human
● MIXTARD 30/70
(Neutral suspension comprising 30% Neutral Insulin Injection and 70% Isophane Insulin Injection [NPH] – human insulin [emp])

Human
● INITARD 50/50
(Neutral suspension comprising 50% Neutral Insulin Injection and 50% Isophane Insulin Injection [NPH] – human insulin [emp])

[illegible] HUMAN INITARD 50/50 (Neutral Suspension comprising 50% Neutral Insulin Injection and 50% [illegible] Insulin Injection [NPH]). HUMAN VELOSULIN, HUMAN INSULATARD, HUMAN MIXTARD 30/70 and HUMAN INITARD 50/50 are manufactured from highly purified human insulin (emp). **PRESENTATION** HUMAN VELOSULIN, HUMAN INSULATARD, HUMAN MIXTARD 30/70 and HUMAN INITARD 50/50 are available in 10ml vials containing 100iu/ml. To provide sensory identification the metal sealing rings of the vial have tactile marks and the vials are also fitted with colour coded tamper-proof caps. **USES** Treatment of Insulin Dependent Diabetics. Human Velosulin is particularly suitable in the treatment of diabetic coma and precoma. **DOSAGE AND ADMINISTRATION** Dosage to be determined by the physician, according to the needs of the patient. Avoid accidental intra-vascular injection. **CONTRA-INDICATIONS AND WARNINGS** Insulin is contra-indicated in hypoglycaemia. In the event of overdosage, glucose should be given either orally or intravenously. Glucagon may also be administered. Human Insulatard, Human Mixtard 30/70, Human Initard 50/50, should not be given intravenously or intravascularly. Treatment with cortico-steroids, oral contraceptives or thyroid hormones may lead to an increase in dosage requirements. Beta-blockers may affect insulin requirements and mask hypoglycaemia. U100 insulin must only be used in U100 syringes. **PHARMACEUTICAL PRECAUTION** Store at 2 to 8 degrees C, protected from sunlight. Do not freeze. **LEGAL CATEGORY** P **BASIC NHS PRICE** HUMAN VELOSULIN, HUMAN INSULATARD, HUMAN MIXTARD 30/70 and HUMAN INITARD 50/50: 10 ml vial £6.95. **PRODUCT LICENCE NUMBERS** Human Velosulin 3132/0031 and 0003/0211. Human Insulatard 3132/0034 and 0003/0212. Human Mixtard 30/70 3132/0037 and 0003/0213. Human Initard 50/50 3132/0040 and 0003/0214.